Accelerated and Safe Expansion of Human Mesenchymal Stromal Cells in Animal Serum-free Medium for Transplantation and Regenerative Medicine
Overview
Physiology
Authors
Affiliations
Human bone marrow mesenchymal stromal cells (hMSC) are currently investigated for a variety of therapeutic applications. However, most expansion protocols still use fetal calf serum (FCS) as growth factor supplement which is a potential source of undesired xenogeneic pathogens. We established an expansion protocol for hMSC based on the use of GMP-produced basic medium LP02 supplemented with 5% of platelet lysate (PL) obtained from human thrombocyte concentrates. Compared to FCS-supplemented culture conditions, we found a significant increase in both colony forming unit-fibroblast (CFU-F) as well as cumulative cell numbers after expansion. This accelerated growth is optimized by pooling of at least 10 thrombocyte concentrates. A minimal requirement is the use of 5% of PL with an optimal platelet concentration of 1.5 x 10(9)/ml, and centrifugation of thawed lysate at high speed. Cells expanded by this protocol meet all criteria for mesenchymal stromal cells (MSCs), e.g. plastic adherence, spindle-shaped morphology, surface marker expression, lack of hematopoietic markers, and differentiation capability into three mesenchymal lineages. MSC at passage 6 were cytogenetically normal and retained their immune-privileged potential by suppressing allogeneic reaction of T-cells. Additionally, gene expression profiles show increased mRNA levels of genes involved in cell cycle and DNA replication and downregulation of developmental and differentiation genes, supporting the observation of increased MSC-expansion in PL-supplemented medium. In summary, we have established a GMP-compatible protocol for safe and accelerated expansion of hMSC to be used in cell and tissue therapy.
Dorofeeva A, Shipounova I, Nikiforova K, Galtseva I, Kuzmina L, Luchkin A Cells. 2024; 13(22).
PMID: 39594656 PMC: 11592413. DOI: 10.3390/cells13221908.
Strecanska M, Sekelova T, Smolinska V, Kuniakova M, Nicodemou A Stem Cell Rev Rep. 2024; 21(2):372-389.
PMID: 39546186 PMC: 11872983. DOI: 10.1007/s12015-024-10812-5.
Tollance A, Prola A, Michel D, Bouche A, Turzi A, Hannouche D Stem Cell Rev Rep. 2024; 20(7):1981-1994.
PMID: 39001964 PMC: 11445347. DOI: 10.1007/s12015-024-10760-0.
Oh S, Jo C, Kim T, Hong C, Lee S, Kang Y Life (Basel). 2023; 13(6).
PMID: 37374070 PMC: 10302647. DOI: 10.3390/life13061286.
Altrock E, Sens-Albert C, Hofmann F, Riabov V, Schmitt N, Xu Q Stem Cell Res Ther. 2023; 14(1):156.
PMID: 37287056 PMC: 10249283. DOI: 10.1186/s13287-023-03386-5.